|Company name||China Biologic Products Holdings, Inc.|
|Live stock price||[stckqut]CBPO[/stckqut]|
|P/E compared to competitors||Good|
|Confident Investor Rating||Good|
|Target stock price (TWCA growth scenario)||$130.58|
|Target stock price (averages with growth)||$135.88|
|Target stock price (averages with no growth)||$92.3|
|Target stock price (manual assumptions)||$121.87|
The following company description is from Reuters: https://www.reuters.com/finance/stocks/company-profile/cbpo
China Biologic Products Holdings, Inc. is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing, and sales of human plasma-based biopharmaceutical products in China. It operates through the manufacture and sales of human plasma products segment. China Biologic has a product portfolio with over 20 various dosage forms of plasma products and other biopharmaceutical products across nine categories.
The Company's products include human albumin, human immunoglobulin, immunoglobulin for intravenous injection (IVIG), human hepatitis B immunoglobulin, human rabies immunoglobulin, human tetanus immunoglobulin, placenta polypeptide, Factor VIII and human prothrombin complex concentrate (PCC). The Company offers human albumin for the treatment of shock caused by blood loss trauma or burn, raised intracranial pressure caused by hydrocephalus or trauma, edema or ascites caused by hepatocirrhosis and nephropathy, prevention and treatment of low-density-lipoproteinemia, and neonatal hyperbilirubinemia. It offers human immunoglobulin and IVIG for the treatment of original immunoglobulin deficiency, such as X chain low immunoglobulin, familiar variable immune deficiency, immunoglobulin G secondary deficiency, secondary immunoglobulin deficiency, such as infection and newborn sepsis, and auto-immune deficiency diseases, such as original thrombocytopenia purpura or kawasaki disease. It offers human hepatitis B immunoglobulin for the prevention of measles and contagious hepatitis. It offers human rabies immunoglobulin for passive immunity from bites or claws by rabies or other infected animals. It offers human tetanus immunoglobulin for the prevention and therapy of tetanus. It offers placenta polypeptide for the treatment for cell immunity deficiency diseases, viral infection and leucopenia caused by various reasons, and also in postoperative healing. It offers Factor VIII for the treatment for coagulopathies, such as hemophilia A and increased concentration of coagulation factor VIII. It offers PCC for the treatment of congenital and acquired clotting factor II, VII, IX, X deficiency, such as Hemophilia B, excessive anticoagulant, and vitamin K deficiency.
Confident Investor comments: At this price and at this time, I think that a Confident Investor can confidently invest in China Biologic Products Holdings, Inc. as long as the indicators that I describe in my book The Confident Investor are favorable.
If you would like to understand how to evaluate companies like I do on this site, please read my book, The Confident Investor. You can review the best companies that I have found (and I probably invest my own money in most of these companies) in my Watch List.
How was this analysis of China Biologic Products Holdings, Inc. calculated?
For owners of my book, "The Confident Investor" I offer the following analysis (you must be logged in to this site as a book owner in order to see the following analysis). If you have registered and cannot see the balance of this article, make sure you are logged in and refresh your browser.
I hope that this makes you a Confident Investor.